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Abstract
Background: Artemisinin resistance in Plasmodium falciparum malaria has emerged in Western Cambodia. This is a
major threat to global plans to control and eliminate malaria as the artemisinins are a key component of
antimalarial treatment throughout the world. To identify key features associated with the delayed parasite
clearance phenotype, we employed DNA microarrays to profile the physiological gene expression pattern of the
resistant isolates.
Results: In the ring and trophozoite stages, we observed reduced expression of many basic metabolic and cellular
pathways which suggests a slower growth and maturation of these parasites during the first half of the asexual
intraerythrocytic developmental cycle (IDC). In the schizont stage, there is an increased expression of essentially all
functionalities associated with protein metabolism which indicates the prolonged and thus increased capacity of
protein synthesis during the second half of the resistant parasite IDC. This modulation of the P. falciparum
intraerythrocytic transcriptome may result from differential expression of regulatory proteins such as transcription
factors or chromatin remodeling associated proteins. In addition, there is a unique and uniform copy number
variation pattern in the Cambodian parasites which may represent an underlying genetic background that
contributes to the resistance phenotype.
Conclusions: The decreased metabolic activities in the ring stages are consistent with previous suggestions of
higher resilience of the early developmental stages to artemisinin. Moreover, the increased capacity of protein
synthesis and protein turnover in the schizont stage may contribute to artemisinin resistance by counteracting the
protein damage caused by the oxidative stress and/or protein alkylation effect of this drug. This study reports the
first global transcriptional survey of artemisinin resistant parasites and provides insight to the complexities of the
molecular basis of pathogens with drug resistance phenotypes in vivo.
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Artemisinin combination therapy (ACT) is recom-
mended by the World Health Organization as the first-
line treatment for falciparum malaria in all endemic
regions [1,2]. The excellent effectiveness and tolerability
of ACTs brought new enthusiasm into world-wide
efforts to eliminate human malaria which until today
accounts for 243 million cases of infection and 863,000
deaths per annum [3]. The core components of ACTs -
artemisinin and its derivatives, provide an important
alternative to quinoline and antifolate-based compounds.
Resistance to these older compounds that emerged on
the Thai-Cambodian border and subsequently spread
across the world has severely compromised their use
and contributed to a dramatic rise in malaria morbidity
prior to introduction of the ACTs in the late 1990’s
[4-7]. Learning from past mistakes, much effort is being
invested in proper management of ACTs in order to
sustain their efficacy and prevent the spread of resis-
tance [1].
In spite of these efforts, there have been sporadic
reports of artemisinin resistance in-vivo and in-vitro for
many years (from Yunnan Province, Southwest China
[8], Vietnam [9] and French Guiana [10]). Although the
biological and clinical significance of these reports were
uncertain [11], these early warning signs suggested a
possibility of emergence of malaria parasites resistant to
artemisinin [12-14]. Recently, unequivocal evidence of
reduced artemisinin susceptibility from Western Cam-
bodia has been reported [15]. Curiously, this was also
the epicenter of chloroquine and sulfadoxine-pyrimetha-
mine resistance. Dondorp et al. (2009) documented
markedly prolonged parasite clearance times (median
PCT 84 hours (interquartile range 60 to 96 hours) in
Pailin, Western Cambodia. This compares with a med-
ian PCT of 48 hours (36 to 66 hours) on the Western
border of Thailand [15]. Since this study, reports of
delayed parasite clearance have emerged in other parts
of the region, including the Thai-Myanmar border [13].
Although it has yet to be established whether artemisi-
nin resistance has spread westward, the possibility of the
spread of resistant parasites through Asia to Africa
would be disastrous.
The mechanism of artemisinin resistance is unknown.
The resistant phenotype detected in Western Cambodia
does not associate with any polymorphisms in the estab-
lished drug resistance markers [15]. In vitro susceptibility
testing of parasites which are cleared abnormally slowly
in vivo, showed essentially no shift in IC50 (50% inhibi-
tion concentration) values in vitro [15]. This apparent
discrepancy between the experimental and the clinical
data may be explained by the reduced susceptibility of
Plasmodium parasites at only the ring stage (first third)
of its 48 hours intraerythrocytic developmental cycle
(IDC) [15,16]. Another phenomenon that has been sug-
gested to explain artemisinin resistance is an increased
propensity for these parasites to form “dormant” (or
quiescent) rings under artemisinin exposure [17,18].
However, this process, suggested by in vitro studies, is
unlikely to explain the slow first order decline in parasite-
mia with time that was observed in Western Cambodian
patients treated with artemisinin-based drugs [19]. The
reduced artemisinin susceptibility phenotype of the resis-
tant malaria parasites exhibits a heritable pattern suggest-
ing that it has a genetic basis [20]. Identifying the genetic
determinants will be crucial for understanding the mole-
cular basis of artemisinin resistance and will also provide
an important molecular tool for epidemiological surveys.
Here we carry out genome-wide gene expression ana-
lyses in order to identify key elements of a transcrip-
tional profile underlining artemisinin resistance. We
show that the P. falciparum parasites with slow clear-
ance after artemisinin treatment exhibit reduced expres-
sion levels of generic metabolic (e.g. glycolysis,
nucleotide metabolism) or cellular (e.g. DNA replica-
tion) pathways in the ring and trophozoite stages but
strong increased expression of essentially all functional-
ities associated with protein synthesis, folding and traf-
ficking in the schizont stages. This specific “tune-up” of
the transcriptional pattern in these resistant P. falci-
parum isolates is associated with altered expression of a
number of genes involved in cell cycle regulation, tran-
scription regulation, chromatin remodeling as well as
intracellular signaling. Altogether these results provide
the first set of testable genetic markers associated with
artemisinin resistance.
Results
Gene expression associated with artemisinin resistance
The main purpose of these studies was to characterize
the transcriptional profile associated with artemisinin
resistance in field isolates of P. falciparum [15]. For this,
we conducted DNA microarray analyses of parasites col-
lected from patients in Pailin, Western Cambodia which
had slow parasite clearance (detectable parasitemia 78-
96 hours following administration of ACTs; isolates
CP025, CP037 and CP040; Additional file 1). For com-
parison we analyzed transcriptomes of additional South-
east Asian isolates collected from Xepon, Savannakhet
Province, Laos (isolates BMT061, BMT076, BMT077,
XPN003), from Mae Sot, Thailand (isolates NHP2094,
NHP4459, NHP4460), and one additional isolate from
Pailin (CP022) with normal clearance (~54 hour). At the
time of collection, all isolates exhibited high synchroni-
city; ~100% parasites were at the ring stage (Additional
file 2). Parasites were then cultured for up to 48 hours
in vitro and total RNA was isolated from samples har-
vested at regular intervals of 2-8 hours.
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Page 2 of 14Similar to previous experiments on in vitro-adapted
isolates [21], these ex vivo samples displayed extensive
stage specificity in transcriptional regulation during
their 48-hour IDC (Additional file 3). However, in con-
trast to the in vitro conditions, the assembled ex vivo
transcriptional profiles indicate considerable differences
in the rates of stage progression (Figure 1a; Additional
file 3). Using a Spearman-rank/Pearson correlation
method, we identified a best fit of the “age” of each ex
vivo experimental point based on peak correlation values
using the previously generated P. falciparum IDC tran-
scriptome in vitro [22]. Here we observed that while at
the time of blood collection, all parasite populations
correspond to the ring stages (10-16 hours post inva-
sion, hpi), the subsequent IDC development was sub-
jected to significant fluctuations (Figure 1b). 5 out of
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Figure 1 Transcriptome analyses of the ex vivo cultured P. falciparum parasites. (a) Transcriptomes of the ex-vivo IDC of 6 field isolates
(representative set of total 11 transcriptomes generated in this study; Additional file 3) from the 3 geographical locations over 48 hour sampling
time. The heat maps represent the mean-centered log2 microarray expression ratios for the P. falciparum genes that were ordered according to
the phase calculated by the Fast Fourier Transformation for the reference in vitro IDC transcriptome. (b) Age estimate of the ex vivo culture time
points for all 11 field isolates. Each colored box represents age estimate (hpi; shown by numbers outside the circle) of the isolate sample relative
to the in vitro reference IDC transcriptome calculated as a best fit Correlation (Spearman rank, see materials and methods). Indicated within each
box is the sampling collection time with respect to the first sampling time denoted by 0 h that correspond to the initial sample collection from
the infected patients prior to culturing. Sampling times with * represent Spearman Rank correlation value less than 0.35 which indicates a
deteriorating synchronicity in the later IDC time points and were excluded from the analysis. Time points included in 3 windows (yellow frame)
corresponding to rings at 12-16 hpi, trophozoites at 24 to 28 hpi and schizonts at 32 to 36 hpi were selected for further analysis. (c) Clusters of
genes with significant differential expression (p-value < 0.01) between the resistant (grey) and susceptible (orange) parasites at ring (14 hpi),
trophozoite (26 hpi) and schizont (34 hpi) stages. Shown are the mean-centered expression log2 ratios for these genes ranked by the z-score
based on the differential expression between the resistant and susceptible isolates. Graphs represent the frequency distribution of the peak
abundance time in the IDC transcriptome for each group of genes: over-expressed (red bars), under-expressed (green bars) or no significant
change in expression (yellow bars). The grey lines represent the middle of the time IDC interval used for the analysis (e.g. ring, (14 hpi),
trophozoite (26 hpi) and schizonts (34 hpi).
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Page 3 of 14the 11 isolates (BMT061 and BMT077 from Laos,
NHP2094 from Thailand and CP040 and CP037 from
Cambodia) exhibited an initial developmental arrest in
the ring stage for 16-24 hours post collection (Figure
1b). In spite of this initial arrest, these isolates reacti-
vated their IDC progression and developed unidirection-
ally through trophozoite and schizont stages. The
progress of the ex vivo cultured P. falciparum isolates
through these later stages was also uneven. The most
extreme example is the Lao isolate BMT077 that
showed additional arrests in the trophozoite and early
schizont stages at 30 to 48 hours post collection (Figure
1a and 1b). Overall, the developmental shifts in the IDC
progression do not correlate with the site of collection,
thus excluding the possibility of experimental bias due
to culturing techniques in each field laboratory. These
data support the previous observation of Lemiuex et al.
(2008) who showed that the ages of 25 P. falciparum
isolates cultured ex vivo for 48 hours fell into a large
interval of 20-44 hpi [23]. In addition, the correlation
coefficients between the mRNA profiles of field isolate
time points and the in vitro control transcriptome are
above 0.55 which demonstrates a good synchronicity of
the ex vivo cultures (Additional file 4). Taken together,
these data show that careful assessment of the parasite
stage of development (age) at any experimental time
point using a reference dataset is essential in ex vivo
analyses of Plasmodium parasites.
To identify genes whose expression is associated with
artemisinin resistance, we compared global transcription
levels between the three artemisinin resistant isolates
and the remaining sensitive isolates by analyzing steady
state mRNA levels in 3 developmental stages; ring (12-
16 hpi: hours post invasion), trophozoite (24-28 hpi)
and schizont (32-36 hpi) (Figure 1b). For that, we
included the experimental time points that show highest
correlation value to the in vitro reference transcriptome
[22] within these sampling intervals (Figure 1b). Overall,
we identified 160 (3.9%), 198 (4.9%) and 373 (9.2%)
genes that are up-regulated and 278 (6.9%), 344 (8.5%)
and 232 (5.7%) genes that are down-regulated in the
resistant parasites (p-value < 0.01) at the ring, tropho-
zoite and schizont stages, respectively (Figure 1c, Addi-
tional file 5). Interestingly, the majority of the genes
over-expressed in the ring stage of the resistant para-
sites correspond to trophozoite- specific genes (peak
mRNA abundance in the normal IDC) and the genes
over-expressed in the schizont stages represent mainly
ring and trophozoite specific transcripts (Figure 1c).
The genes up-regulated in the trophozoite stage are
e v e n l yd i s t r i b u t e db e t w e e nr i n ga n ds c h i z o n ts p e c i f i c
transcripts. This indicates that the transcriptional up-
regulations associated with artemisinin resistance consti-
tute either accelerated timing of transcription of
trophozoite and schizont genes at the ring stage, or pro-
longed expression of ring and trophozoite transcripts in
the schizont stage. Intriguingly, this pattern was not
observed for down-regulated genes whose expression in
artemisinin resistant parasites coincides with their
expected stage specificity, albeit at lower levels than
expected in the artemisinin sensitive isolates (Figure 1c).
Taken together, these results suggest that artemisinin
resistance is associated with specific modifications of
the IDC transcriptional cascade that involve a large
number of genes and presumably alter the levels and
temporal distributions of biological and cellular
functions.
Functional analysis of artemisinin resistance associated
genes
To evaluate the physiological relevance of the identified
differential gene expression, we utilized Gene Set
Enrichment Analysis (GSEA) [24] to explore functional
assignments of genes associated with artemisinin resis-
tance (Figure 2; Additional file 6). We found that genes
down-regulated at ring and trophozoite stages represent
well established biochemical and cellular pathways such
as glycolysis, pentose phosphate shunt, REDOX, nucleo-
tide and glutathione synthesis, and the TCA cycle (Fig-
ure 2a, b). Under normal growth, these pathways reach
transcriptional peaks during the early stages of the IDC,
so down-regulation indicates reduced expression in
young parasites. In addition, we observed a significant
down-regulation of genes associated with DNA replica-
tion and protein degradation in the trophozoite and
schizont stages (Figure 2a, b; Additional file 6, 7). This
down-regulation may represent a delayed onset of
expression that normally starts during at the ring/tro-
phozoite transition. At the schizont stage, the artemisi-
nin resistant parasites were characterized by marked
over-expression of genes that belong to many pathways
associated with protein synthesis, folding and trafficking
(Figure 2a, b). These include genes involved in ribosome
assembly and maturation, chaperone-assisted protein
folding, translational initiation and elongation (Addi-
tional file 6, 7). In addition, we observed up-regulation
of several additional pathways such as RNA metabolism
and hemoglobin degradation, both of which could con-
tribute to increased capacity of protein synthesis in
these parasites by boosting global levels of RNA tran-
scripts and concentration of amino acids produced by
the food vacuole (Additional file 6, 7). Investigating indi-
vidual genes in the affected pathways, we observed that
w h i l ei ns o m ec a s e st h ed i f f e r e n t i a le x p r e s s i o na f f e c t s
most genes (such as glycolysis or REDOX), in other
pathways (such as translational initiation or proteasome
degradation), only a fraction of genes exhibit differential
expression (Additional file 8). These latter genes may
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Page 4 of 14represent crucial regulatory or rate limiting steps in
these biological processes.
In summary, our data suggest that the specific modu-
lation of the IDC transcriptional cascade observed in
artemisinin resistant parasites has at least two major
physiological implications that include: down-regulation
of metabolic and cellular pathways in the first half of
the IDC (up to 28 hpi) and prolonged transcription up-
regulation of functionalities associated with protein
synthesis and their supporting activities in the late
stages (~36 hpi). Interestingly, this transcriptional pro-
gram was observed in all three Western Cambodian iso-
lates with the delayed clearance but not in the isolate
collected in the same region (CP022) that had a normal
clearance time (Figure 2b; Additional file 7). This sug-
gests that the altered transcriptional pattern is not a
simple reflection of geographical or other generic differ-
ences between P. falciparum isolates but is indeed asso-
ciated with artemisinin resistance.
Differential expression of regulatory proteins may
contribute to artemisinin resistance
Artemisinin resistance in Western Cambodia was shown
to exhibit a genetically inheritable pattern [20]. Thus it
is feasible to speculate that the broad transcriptional
changes associated with this phenotype may have
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(b)
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Figure 2 Functional analyses of differentially expressed genes in the artemisinin resistant parasites. (a) The heat maps depict differential
gene expression in the trophozoite and schizont stages and the mean-centered log2 ratios of mRNA levels between the resistant and
susceptible isolates (for the complete set of all stages, see Additional file 6). Here the genes were ranked according to descending z-score (SNR)
by correlating the expression profiles to the phenotypic class. Gene Set Enrichment Analysis (GSEA) revealed functional pathways down-
regulated in trophozoites and up-regulated in schizonts of the resistant parasites shown in the side bar diagrams and ordered by the nominal p-
value. Positions of the genes belonging to each identified pathway are indicated by the colored bars in the corresponding z-score ordered gene
distribution. (b) Graphs illustrate several functional pathways with significant differential expression between the resistant and susceptible
parasites in the three stages. Data points represent the average log2 expression ratio for the isolates in each of the groups and across all genes
belonging to the pathway for ring (14 hpi), trophozoite (26 hpi) and schizont (34 hpi) stages of the resistant (green triangle) and susceptible
(blue diamond) isolates. Plotted are best fit polynomial curves and error bars that indicate the standard deviation amongst the isolates. Included
are the average expression ratios for the artemisinin sensitive Cambodian isolate, CP022 (purple circle). For reference, the data are projected onto
the centered mRNA abundance profiles of the in vitro IDC transcriptome (red square).
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Page 5 of 14resulted from a small number of genetic mutations in
key regulatory proteins such as global transcription fac-
tors, chromatin remodeling-associated proteins or cell
cycle regulators. We sought to explore the transcrip-
tional data to find further clues for such underlying
genetic determinants. For that, we inspected the genes
whose expression was changed consistently in the three
individual stages as these may be linked with a putative
genetic variation (possibly in their regulatory elements).
To identify such genes, we determined the rank product
score for differentially expressed genes and classified
them based on their differen t i a le x p r e s s i o ni na l l3
stages (Figure 3a; Additional file 5). Interestingly, the
rank distribution was skewed towards lower values
where larger numbers of genes show lower than
expected rank scores (Figure 3a). This indicates that
there are more genes consistently down-regulated in the
artemisinin resistant parasites in all three stages com-
pared to the up-regulated genes that tend to be over-
expressed in only one or two of the IDC developmental
stages.
Functional enrichment analyses of the top 5% of genes
from both extremes of the distribution (see Figure 3a
grey boxes) did not uncover any additional functional
groups compared to the stage-wise GSEA (Figure 2),
however, visual inspection of these gene groups identi-
fied 41 putative transcription regulators, of which 22 are
under-expressed and 19 are over-expressed. These
include transcription factors, RNA binding proteins, cell
cycle regulators, chromatin remodeling associated
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 03 23 43 63 84 04 24 44 64 85 0
PFA0510w:: bromodomain protein, putative
PF14_0350:: N-acetyltransferase (HAT), putative 
L
o
g
2
 
r
a
t
i
o
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50
PF14_0416:: zinc finger protein, putative
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 03 23 43 63 84 04 24 44 64 85 0
PF14_0079:: transcription factor with 
AP2 domain(s), putative
L
o
g
2
 
r
a
t
i
o
Over-expressed
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 500 1000 1500 2000 2500 3000 3500 4000
Gene order
R
a
n
k
 
P
r
o
d
u
c
t
 
S
c
o
r
e
Rank Product Score 
(Observed)
Rank Product Score 
(Randomized)
(b) (a)
-1
-0.5
0
0.5
1
1.5
2
0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 03 23 43 63 84 04 24 44 64 85 0
PFE0610c:: CDK-activating kinase 
assembly factor, putative
-1.5
-1
-0.5
0
0.5
1
1.5
2
0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 03 23 43 63 84 04 24 44 64 85 0
PFI1260c:: Histone deacetylase HDAC1
0 48hpi 0 48hpi
L
o
g
2
 
r
a
t
i
o
Under-expressed
(c) (d)
-3
-2
-1
0
1
2
3
4
PFA0510w::bromodomain 
protein
PF13_0141::Lactate 
dehydrogenase
PF11_0061::Histone 4 PF14_0057:: RNA-
binding protein
PF14_0079:: AP2 TF
real-time PCR microarray
       
       
       
       
CP040 CP040 CP025 CP025 CP037 Resistant
Sensitive
Stage
Change
BMT076 BMT076 BMT077 BMT077 NHP2094
14hpi (ring) 14hpi (ring) 26hpi (trophozoite) 34hpi (schizont) 26hpi (trophozoite)
     
L
o
g
2
 
e
x
p
r
e
s
s
i
o
n
 
r
a
t
i
o
 
(
r
e
s
i
s
t
a
n
t
 
v
s
 
s
e
n
s
i
t
i
v
e
)
Dd2
Sensitive
Resistant
CP022 
(Sensitive)
Legend:
0 48hpi 0 48hpi
0 48hpi 0 48hpi
-5
-4
-3
-2
-1
0
1
2
3
0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 03 23 43 63 84 04 24 44 64 85 0
PF11_0061::Histone 4
L
o
g
2
 
r
a
t
i
o
PF14_0057::RNA-binding protein
-1.5
-1
-0.5
0
0.5
1
1.5
2
0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 03 23 43 63 84 04 24 44 64 85 0
0 48hpi 0 48hpi
Figure 3 Classification of differentially expressed genes across the whole IDC and validation of differential expression of 5 genes by
qPCR. (a) Plot of the Ranked Product Score for all 4,015 genes calculated from the geometric mean of the ranked z-scores of the genes in the 3
stages in the generated transcriptome (orange) and in the randomized dataset (green) (for details see material and methods). The graphs
represent 4 over (b) and 4 under-expressed (c) genes in the resistant parasites with potential regulatory functions present in the top 5% of each
extreme of the rank product distribution, respectively ((a) grey boxes). Data points represent the mean log2 expression ratios of the genes in the
resistant (green triangle), susceptible Lao and Thai (blue diamond), and susceptible Cambodian isolates (CP022, purple circle) across the three
selected stage intervals. The data are projected onto the gene expression profiles analyzed by the in vitro IDC transcriptome (red square). Error
bars reflect the standard deviation of the log2 ratios for each data point. (d) Bars represent the log2-transformed fold change measured from
relative quantification of a resistant versus a sensitive isolate using PFC0965w as a reference control gene in real-time PCR experiments (teal) and
plotted alongside the microarray expression ratios (light blue). Error bars reflect the standard deviation of the log2 ratios over triplicates.
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Page 6 of 14proteins, histone modification enzymes as well as his-
tones (Figure 3b, c, for complete list see Additional file
5 Sheet “Rank product score”). The most remarkable
examples are strong down-regulation of genes coding
for histone deacetylase 1 protein (HDAC1) (PFI1260c),
recently proposed to play a major role in the transcrip-
tional regulation [25], and CDK-activating kinase assem-
bly factor (PFE0610c) whose paralogue was shown be
associated with HDAC1 in P. falciparum [26]. Also, the
artemisinin resistant parasites show a considerable up-
regulation of the AP2 containing transcription factor
(PF14_0079), bromo-domain containing protein
(PFA0510w), putative histone acetyltransferase (hat;
PF14_0350), zinc finger protein (PF14_0416), and the P.
falciparum homologue of yeast histone chaperone
Rttp106-like transcriptional regulator (PFE0870w). In
addition to these DNA interacting regulatory proteins,
we identified 10 genes encoding the RNA-recognition
motif (RRM) that are involved in regulating mRNA sta-
bility or translational repression. Quantitative real-time
PCR carried out with 4 of these genes (PFA0510w,
PF14_0079, PF11_0061 and PF14_0057) further con-
firmed that these genes are significantly differentially
expressed between the resistant and sensitive isolates
(Figure 3d). Differential expression of these genes
encoding regulatory factors may contribute to the global
changes in the transcriptome observed in the artemisi-
nin resistant parasites.
Copy number variations (CNV) and genotypes of
artemisinin resistant isolates
Several recent studies have demonstrated a frequent
occurrence of gene copy number variants (CNV) in P.
falciparum and linked these to differential gene expres-
sion in field isolates and laboratory strains [27-32]. This
can contribute to the variability in drug sensitivities
observed among isolates [33,34]. We carried out com-
parative genomic hybridizations with genomic DNA of
the four Cambodian and two Lao isolates and demon-
strated that CNV profiles exhibit a clear segregation
between these two groups (Figure 4a). Among the 138
genes occurring within the 93 CNV detected segments
are Histone 4, GTP cyclohydrolase I (pfgch1), hyp4/5
exported proteins, phist genes and Maurer’sc l e f tt w o
transmembrane proteins (pfmc-2tm) [27-32]. Increased
copy number of pfgch1 has been previously linked with
resistance to antifolate antimalarial drugs and its ampli-
fication in the Cambodian isolates (p-value = 0.002) may
reflect the prolonged use of these drugs in this region
[35]. Other newly identified CNVs include several
hypothetical genes; an autophagocytosis associated pro-
tein and Zn
2+/Fe
2+ permease (data not shown). Overall
we observed strong similarities amongst the Cambodian
isolates, however none of the identified CNV could be
associated with artemisinin resistance. This genetic
coherence among the four Cambodian isolates contrasts
with their transcriptional heterogeneity and indicates
that copy number differences are strongly associated
with differentiation in geographical origins. More
genetic studies with large number of isolates will be
required to assess the role of CNVs in artemisinin
resistance.
In addition to the CGH analysis, we carried out “stan-
dard” genotyping of genes coding for merozoite surface
proteins: msp1, msp2 and glutamate-rich protein: glurp
together with sequencing of drug-resistant markers:
multidrug resistant protein 1 (pfmdr1) and dihydrop-
teroate synthase (pfdhps). This analysis revealed that the
four Cambodian and two Lao isolates are genetically dis-
tinct from each other carrying different alleles of the
tested genes (Figure 4b). Of these, CP025 and CP037
appeared highly related, exhibiting identical msp1 and
msp2 nested PCR products of KO33 and IC/3d7 alleles
(Figure 4b). However, these two isolates differ in 2 non-
synonymous SNPs of codons K214Q and K1181T and a
synonymous SNP in codon 171 in the pfmdr1 gene (Fig-
ure 4c). In addition, CP025 and CP037 exhibit subtle
differences in their CNV pattern as measured by CGH
(Figure 4a). Interestingly, we found that none of the 6
isolates carry the N86Y pfmdr1 mutation (Figure 4c)
w h o s ep r e s e n c ei sf r e q u e n t in many Southeast Asian
regions [36] and which is commonly associated with
chloroquine resistance and mefloquine hypersensitivity
[ 3 7 ] .F u r t h e r m o r e ,w eo b s e r ved significant haplotype
sharing amongst analyzed isolates such as CP040 and
CP022 that share the “NEFSNVD” haplotype of pfmdr1,
containing the non-synonymous Y184F mutation. More-
over, CP025, CP037, CP040, CP022 and XPN003 share
the IAGEAA haplotype of pfdhps with non-synonymous
triple mutants S436A, G437A and K540E, which were
previously linked to resistance to sulfadoxine-pyrimetha-
mine [38,39]. The mutations in dhps may reflect the
selection pressure as a result of an extensive antifolate
drug use in this region over several decades. In sum-
mary, these genetic studies suggest that while the Wes-
tern Cambodian isolates are not identical isogenic
clones, they share a recent common ancestor that is evi-
dent from their CNV profiles. Hence, the highly unique
and also uniform CNV pattern identified in these para-
sites may represent a genetic background that contri-
butes to development of artemisinin resistance and
possibly other drug resistant phenotypes in this region.
Discussion
Mechanism of artemisinin resistance
Artemisinin resistance of P. falciparum is a major threat
to malaria control. Understanding its molecular basis is
thus essential for determining treatment strategies,
Mok et al. BMC Genomics 2011, 12:391
http://www.biomedcentral.com/1471-2164/12/391
Page 7 of 14mapping the spread of resistance and guiding elimina-
tion [20,40-44]. Mutations or amplification of genes
encoding transporters or target enzymes have been
identified as resistance mechanisms to other antimalarial
drugs. It is possible that resistance to artemisinin is
unlike these classical mechanisms in vitro but instead
results from a complex series of genetic and epigenetic
events affecting multiple pathways. Here we showed that
artemisinin resistant parasites are characterized by a
specific modulation of the IDC transcriptome that
affects a broad spectrum of genes and biological func-
tions. First, we detected a specific down-regulation of
many ring stage-specific metabolic pathways such as
energy metabolism, nucleotide synthesis etc. Second, the
progress to mature schizont stages was marked by sig-
nificant increase in transcription of genes associated
with essentially all functionalities involved in protein
metabolism (Figure 2). Based on these two observations,
we propose a plausible model for molecular basis of the
artemisinin resistance observed in these Cambodian iso-
lates that is founded on two (possibly independent)
events: (i) Limited metabolic activity of the ring stages
could lead to lower levels of hemoglobin digestion, less
ferrous ions produced and thus reduced activation and
conversion of artemisinin drugs to reactive intermedi-
ates [45]. This effect may be linked to the high preva-
lence of hemoglobinopathies, especially Hemoglobin E
and a-thalassemia in this area conferring increased oxi-
dant stress [46,47]. This is possibly compounded by dec-
ades of unregulated artemisinin use in Western
Cambodia which may select for parasites with greater
resistance to oxidant stress during the ring form devel-
opment. Alternatively, the lower metabolic activities of
the ring stages may be a prerequisite of the ability of
the resistant parasite to become dormant under the
artemisinin pressure as demonstrated by several in vitro
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CP022  AAT(N) GAA(E) TTT(F) AGT(S) AAT(N)  GTA(V)  GAT(D) 
CP025  AAT(N) GAA(E) TAT(Y) AGT(S) AAT(N) GTA(V) GAT(D) 
CP037  AAT(N) GAA(E) TAT(Y) AGT(S) AAT(N) GTA(V) GAT(D) 
CP040  AAT(N) GAA(E) TTT(F) AGT(S) AAT(N)  GTA(V)  GAT(D) 
BMT077  AAT(N) GAA(E) TAT(Y)  AGT(S)  AAT(N) GTA(V) GAT(D) 
XPN003  AAT(N) GAA(E) TAT(Y)  AGT(S)  AAT(N) GTA(V) GAT(D) 
3d7  AAT(N) GAA(E) TAT(Y) AGT(S) AAT(N) GTA(V) GAT(D) 
 
Pfmdr1   79  171  208  214  1181 
CP022  GGT(G)  ATC(I) TGC(C) AAG(K)  AAA(K) 
CP025  GTT(V)  ATC(I) TGC(C) CAG(Q) AAA(K) 
CP037  GTT(V) ATA(I) TGC(C)  AAG(K) ACA(T) 
CP040  GGT(G)  ATC(I) TGC(C) AAG(K)  ACA(T) 
BMT077  GGT(G)  ATC(I) TGC(C) AAG(K)  AAA(K) 
XPN003  GGT(G)  ATC(I) TGC(C) AAG(K)  ACA(T) 
3d7  GGT(G) ATA(I) TGT(C) AAG(K)  AAA(K) 
 
Pfdhps   431  436  437  540  581  613 
CP022  ATA(I)  GCT(A) GGT(G) GAA(E) GCG(A) GCC(A) 
CP025  ATA(I)  GCT(A) GGT(G) GAA(E) GCG(A) GCC(A) 
CP037  ATA(I)  GCT(A) GGT(G) GAA(E) GCG(A) GCC(A) 
CP040  ATA(I)  GCT(A) GGT(G) GAA(E) GCG(A) GCC(A) 
BMT077  ATA(I) TCT(S) GCT(A) AAA(K)  GCG(A)  GCC(A) 
XPN003  ATA(I)  GCT(A) GGT(G) GAA(E) GCG(A) GCC(A) 
3d7  ATA(I) TCT(S) GGT(G) AAA(K)  GCG(A)  GCC(A) 
 
(a)
Common SNPs
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Common SNPs
Figure 4 CGH analysis of artemisinin resistant isolates, Genotyping of isolates and Sequencing of drug-resistant genes to determine
haplotypes. (a) The heat map represents hierarchical clustering of CGH signal (against 3d7 genome) for 257 microarray oligonucleotide
elements representing 138 genes in 93 CNV regions identified by GADA analysis (see material and methods). (b) Visualization of msp1, msp2 and
glurp nested PCR products of the 6 isolates on a 2.5% agarose gel shows distinctive patterns of product sizes for each clone, except for CP025
and CP037. (c) Tables depict the commonly and rarely found single nucleotide polymorphisms (SNPs) found based on the codon position (top
row) and the sequenced bases of the various isolates and corresponding amino acid in brackets. Highlighted in yellow are the codons with
mutations compared to wild type 3d7.
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Page 8 of 14analyses [17,18]. Although this phenomenon is unlikely
to be the major factor in artemisinin resistance, it is
worth noting that the results obtained in our study are
in agreement with the transcriptional analyses of the in
vitro derived artemisinin tolerant parasites that include
mRNA levels of the hypoxanthine phosphoribosyl trans-
ferase (PF10_0121), a cell cycle regulator (PFE1415w)
and a Heat Shock Protein 70 kDa (PF08_0054) (Addi-
tional file 9) [40]. (ii) The increased activity of protein
metabolism may contribute to the resistance by with-
standing the damaging effects of artemisinin on para-
site’s proteins by increasing rates of protein turnover
and synthesis and thus compensate for loss of active
proteins. This is consistent with the presumed artemisi-
nin mode of action in which the drug inflicts substantial
damage to the parasite cell either by an oxidative stress
(via reactive free radicals) or by direct alkylation of a
wide spectrum of cellular components such as proteins,
heme, and lipids [48-53].
Transcriptional regulation and artemisinin resistance
It is important to note that the differences in mRNA
levels linked to artemisinin resistance were not the most
dramatic transcriptional differences detected among the
field isolates. Functional enrichment analysis of genes
that vary the most in their expression among the 11 field
isolates irrespective of their artemisinin sensitivities,
revealed a distinct set of functionalities that varied in
gene expression amongst field isolates in general. These
include mainly genes encoding proteins of host-parasite
interactions, Maurer’sc l e f t sp r o t e i n s ,i n v a s i o n - r e l a t e d
proteins, as well as factors of fatty acid metabolism, gly-
colysis and hemoglobin digestion (Additional file 10).
This indicates that the observed transcriptional differ-
ences between artemisinin resistant and sensitive strains
may represent a new event in transcriptional differentia-
tion of field isolates that does not occur in other parasite
populations. Although very little is known about molecu-
lar factors of transcriptional regulation in P. falciparum,
a number of previous studies [25,54-57] have indicated
the existence of broad range regulatory mechanisms that
affect large groups of genes controlling the progression
of the Plasmodium life cycle. Although more studies that
involve large epidemiological surveys followed by exten-
sive molecular analyses will have to be carried out to sup-
port such putative mechanism s ,h e r ew ee x p l o r e dg e n e s
whose expression was affected in all three developmental
stages in the resistant Western Cambodian parasites.
One of the most remarkable examples of consistently
down-regulated genes is pfhdac1 and its putative inter-
acting proteins partner CDK-activating kinase, both of
which show dramatic down-regulation in all three devel-
opmental stages (Figure 3). In our recent study, we
showed that HDAC activities play a highly dynamic role
in regulating the transcriptome of the Plasmodium life
cycle and that their inhibition leads to widespread tran-
scriptional changes. Intriguingly, the transcription profile
of the resistant parasites is reminiscent of the effect of
HDAC inhibitors on the P. falciparum gene expression
in which most gene induction represent accelerated tran-
scription in the ring and trophozoite stages and pro-
longed mRNA expression during the schizont stage [25].
Another gene whose differential expression is signifi-
cant is histone 4 (PF11_0061). Histone 4 is the only
nucleosomal subunit present as a single copy gene and
thus its down-regulation could have severe implication
on the nucleosomal assembly during the P. falciparum
schizont stage. Depletion of histone 4 in both yeast and
human cells causes an arrest or dramatic delay in the
progression of the S-phase, which is caused by insuffi-
cient nucleosomal assembly and subsequently inhibition
of DNA synthesis [58,59]. We observed a modest but
statistically significant decrease of histone 4 in the arte-
misinin resistant P. falciparum parasites (Figure 3d) that
could analogously lead to a delayed onset of schizogony
a n dt h u sp r o l o n g e de x p r e s s i o n of genes associated with
the typical trophozoite functions such as protein synth-
esis and hemoglobin digestion (Figure 2). Since the
CNV profiles were similar among the four Cambodian
isolates regardless of their tolerance level to artemisinin,
more studies will be needed to understand their role in
regulating transcriptional levels in artemisinin resistant
parasites. More importantly, the coherence of CNV pro-
files among the Cambodian isolates indicates that the
parasites in this region share a recent common ancestor.
Similar conclusion was made by an admixture study car-
ried out in Southeast Asia that demonstrated a sub-
group of recently expanded parasite populations in Wes-
tern Cambodia [60]. This could be a result of intense
administration of a successive number of antimalarials
from chloroquine to mefloquine to sulfodoxine-pyri-
methamine to treat malaria cases in the Western Cam-
bodian region over the last 80 years. It is plausible that
a population with a restricted genotype has emerged
with a genetic background that has higher propensity to
give rise to resistance of the P. falciparum parasites to
artemisinin.
Conclusions
Here we present the most comprehensive transcriptional
analysis of the artemisinin tolerant malaria parasites col-
lected at the site of its origin, Western Cambodia.
Although much more extensive research on multiple
levels will be needed to elucidate the complete mechan-
ism, the results from these studies provide the first tes-
table hypotheses regarding both the global pattern of
the transcriptional cascade and candidate genes involved
in artemisinin resistance.
Mok et al. BMC Genomics 2011, 12:391
http://www.biomedcentral.com/1471-2164/12/391
Page 9 of 14Methods
Sample collection from patient and during ex-vivo IDC
On admission to the hospital and upon consent, 10 ml
of total infected blood was taken from each adult P. fal-
ciparum-infected patient from the various field sites
(Pailin, Cambodia; Xepon, Savannakhet Province, Laos;
Mae Sot, Thailand). Samples were filtered by CF11 col-
umn purification to remove white blood cells and obtain
infected red blood cells which were subjected to in vitro
c u l t u r ef o ro n eg e n e r a t i o no ft h eI D Co v e r4 8h o u r s .
For every isolate, a total of 6 to 10 samples were har-
vested at regular intervals of 2 to 8 hours throughout
the IDC. 100-500 μl of packed red blood cells with 1% -
10% parasitemia were collected per time point sampling.
RNA extraction, cDNA synthesis & Microarray
Hybridizations
Total RNA was isolated from all ex-vivo samples using
the trizol-chloroform-isopropanol precipitation method
as described [21]. Synthesis of target DNA for microar-
ray hybridization was carried out as previously described
[27,61] with the following exceptions: Reverse-transcrip-
tion was carried out using 200 units of SuperScript II
enzyme (Invitrogen, USA) to create the first strand
cDNA. Following PCR amplification with 19 cycles and
purification of the product, a total of 5-7_g of double-
stranded DNA was obtained for each sample. From this,
4 μg of DNA was labeled with fluorescent Cy5 dye and
used for the microarray hybridization (GE Amersham,
USA). For the reference pool, cDNA consisting of all
IDC stages of 3d7 strain was made identically and
labeled with Cy3 dye. Equal amounts of labeled sample
from each time point and reference RNA pool was
hybridized on the 70-mer P. falciparum cDNA microar-
ray chip containing 10,680 oligonucleotides representing
5,343 coding genes [62]. The microarray hybridization
was carried out at 65°C in the automated MAUI hybri-
dization system (BioMicro Systems, USA). The microar-
ray chips were scanned using the GenePix 4000 B
scanner and GenePix Pro 6.0 software (Molecular
Devices, USA).
Microarray data Processing and analysis
The initial acquired microarray data was filtered to
include microarray hybridization “spots” with at least
95% pixels having signal intensity above 2 standard
deviations from background for both Cy3 and Cy5 fluor-
escence intensity. Subsequently, array Lowess normaliza-
tion was applied to all arrays as implemented by Acuity
4.0 software (Molecular Devices, USA). The assembly of
the IDC transcriptome for all isolates was carried out
using Fast Fourier Transform as previously described
[21] with following modifications; the expression value
for each gene is represented by an average value
obtained from all oligonucleotide probes in each tran-
script/gene. To construct the phaseogram of reference
IDC transcriptome for further comparisons, genes with
expression data in at least 19 out of 24 (80%) time
points were extracted, any missing values were imputed
and polynomial fit of order 6 was applied to generate
smoothed data. This was then analyzed by Fast Fourier
Transform method and all 4,634 genes with the mean-
centered gene expression log2 ratios were sorted accord-
ing to phase from -π to π (Additional file 2). The pha-
seogram of each isolate contains mean-centered gene
expression data ordered according to the phase value.
For each isolate’s time course, only genes having at least
80% of data present were extracted and any missing
data values were imputed by KNN (K
th nearest neigh-
bor) method using R version 2.10.1 package and impute
function.
Mapping parasite’s sample age to the reference IDC
To map the age of each isolate time point sample rela-
tive to the progression of in vitro lab strain IDC, Spear-
man Rank Correlation Coefficient (SRCC) values
between global mRNA profiles for each isolate time
point and time points in the reference IDC transcrip-
tome [22] (every 2 hour sample time point of the in
vitro Dd2 lifecycle) were calculated. The stage (hpi) cor-
responding to the peak SRCC value was assigned as the
best estimate of the age of the parasite for that sample
collection (see colored box in Figure 1b). Only samples
which had SRCC above a value of 0.35 were considered
in the following analysis. To select time points for
downstream differential analysis, we calculated the fre-
quency distribution of isolate time points found within a
window of three consecutive hpi and selected three win-
dows based on the highest representation of isolates
with at least one sampling time point found within that
window. Isolates with sample time points found within
the 4 hour windows of 12-16 hpi, 24-28 hpi and 32-36
hpi corresponding to mid-ring, early-trophozoite and
early-schizont stages were grouped accordingly as repre-
senting these stages.
Identifying Differentially Expressed Genes
Z scores were calculated by correlating the average gene
expression to noise ratio (SNR) of the mRNA expression
ratios to the clearance phenotype (ie. resistant - CP025,
CP037, CP040 vs. sensitive - CP022, BMT061, BMT077,
BMT076, XPN003, NHP2094, NHP4459, NHP4460) and
normalized to sample size.
Z =
2 √
N.
μa − μb
σa + σb
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Page 10 of 14Where μa and μb are the mean expression log2 ratio of
resistant and sensitive parasites respectively and sa and
sb are the standard deviations of resistant and sensitive
group respectively. Differentially expressed genes were
defined with p-value cut-off < 0.01 from Student t- dis-
tribution of the z-scores carried out for the 3 stages.
Gene set enrichment analysis [24] was carried out on
the resistant vs. sensitive parasites using SNR. A total of
1,261 gene sets comprising of KEGG pathways [63],
MPM and functional groups based on previous studies
[21,64-66] were included. Nominal p-value and false dis-
covery rate (FDR) were calculated for each gene set
f r o mt h eo b s e r v e dn o r m a l i z e de n r i c h m e n ts c o r e( N E S )
against a null distribution using a gene set-based permu-
tation test. Gene sets with p-value < 0.05 and FDR <
25% were considered to be statistically significant.
Calculate Timing of Peak mRNA abundance of genes
The time of peak expression for each gene (represented
by hpi) is derived from the phase of the Fourier trans-
formation of the in vitro reference transcriptome using
the formula:
PeakAbundanceTime

hpi

=2+

46(θ + π)
2π

Where θ is the phase value of the gene.
Calculation of Rank Product Score
Using the z-scores (see above) of each gene, we sorted
the genes according to descending order and assigned a
numerical rank score for every gene at each of the three
stages. In order to generate a list of genes consistently
up/down-regulated in the three stages, we calculate the
geometric mean of the rank score to determine the rank
product (RP) score of each gene using the formula:
RPg = [rankg
14hpi × rankg
26hpi × rankg
34hpi]/N3
Where the rankg
14hpi,r a n k g
26hpi,r a n k g
34hpi corre-
sponds to the rank score of the gene at 14 hpi, 26 hpi
or 34 hpi respectively.
Copy Number Difference Analysis
To identify significant CNVs among the 6 isolates, we
performed comparative genomic hybridization using
genomic DNA extracted from the isolates (CP022,
CP025, CP037, CP040, BMT077, XPN003) against geno-
mic DNA of the reference lab strain of 3d7 as previously
described [27]. We carried out subtraction analysis
between any 2 isolates in multiple pair-wise compari-
sons and considered only segments that have at least
1.7-fold change in mean amplitude and T-coefficient
greater than 3.5 in minimum 2 consecutive gene probes
between any 2 isolates as significant. This was per-
formed using the Genomic Alteration Detection Analy-
sis (GADA) program in R package [67].
Real-time PCR (qPCR)
Real time PCR and the relative quantification of gene
expression was performed in at least triplicates using
the comparative CT method of calculating -ΔΔCt values
and taking PFC0965w as a reference control gene, as
previously described [62].
Genotyping of isolates and Sequencing of pfmdr1 and
pfdhps genes
Genotyping of msp1, msp2 and glurp were carried out as
previously described [68] with positive control of lab
clone, 3d7, in a nested PCR reaction and products were
visualized on a 2.5% agarose gel. Nested PCR reactions
were performed as previously described [69] to generate
fragments of mdr1 and dhps genes containing com-
monly found SNPs and products were sequenced with
corresponding forward and reverse primers using ABI
Big Dye Terminator cycle sequencing method.
Additional material
Additional file 1: Parasite density over course of treatment and
treatment outcomes. Plot of the parasite densities (relative to starting
parasite numbers on admission) from the time of patient’s1
st admission
date up to 100 hours after admission. Of the 4 isolates from Pailin,
Cambodia, only 3 (CP025 (red), CP037 (green), CP040 (blue)) display
significant delayed parasite clearance time (pct) of 78 and 96 hours from
the patients after treatment while CP022 (purple) parasites was cleared
earlier at 54 hours after treatment. The initial parasite numbers upon
admission (para0) and parasite reduction ratio at 24 hours (prr24) and 48
hours (prr48) are included in the table. Artesunate and mefloquine
treatment regimes administered to the patients are listed (box).
Additional file 2: Information about the sampling times,
parasitemia of the ring, trophozoite and schizont stages of the 11
isolates. na: information not available.
Additional file 3: Ex-vivo transcriptomes generated of the 11 P.
falciparum field isolates from South East Asia. Transcriptomes of the
ex-vivo IDC of all 11 field isolates from the 3 geographical locations
measured over 48 hour sampling time. Only genes with at least 80% of
time points with a positive signal were included for each of these
transcriptomes. The phaseograms were constructed by ordering the
mean-centered log2 microarray expression ratios to the genes ordered
by phase calculated from the Fast Fourier Transformation of the Dd2
reference in vitro lifecycle.
Additional file 4: Distribution of Pearson correlations between all
isolates for the 3 stages. Including isolate time points that correspond
to the 3 stages - 14 hpi, 26 hpi and 34 hpi - graphs shown are average
Pearson Correlations calculated from multiple pair wise comparisons
between all isolates (graphs on left panel) and the average of the PCC
for the resistant and sensitive parasites (graphs on right panel) at 14 hpi
(a), at 26 hpi (b) and at 34 hpi (c). Error bars represent the standard
deviation of all the pair-wise comparisons.
Additional file 5: Sheets 1-3 lists log2 expression data of all genes
for the isolates grouped by ring (14 hpi), trophozoite (26 hpi) and
schizont (34 hpi) stage and their corresponding z-scores (signal to
noise) and p-values using student t-distribution. Genes with
significant difference in expression between the resistant and sensitive
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Page 11 of 14isolates (p-value < 0.01) are highlighted in orange. Sheet “rank product
score” lists all genes including putative transcriptional regulators
(including those with zinc finger, bromodomain, etc., domains predicted
by PFAM, Histone/HDAC/HAT-related, AP2-domain containing and
potential cell cycle regulators) used in the analysis and their
corresponding z-scores and rank product scores for ring (14 hpi),
trophozoite (26 hpi) and schizont (34 hpi) stages.
Additional file 6: Functional analyses of differential expression in all
stages of the artemisinin resistant parasites. For each of the 3 stages,
genes were ranked according to the z-score by correlating the
expression profiles to the phenotypic class. The mean-centered log2
ratios for each gene of the resistant (CP025, CP037, and CP040) and
sensitive (CP022, BMT061, BMT076, BMT077, XPN003, NHP2094, NHP4459,
NHP4460) isolates are represented in these clusters. Gene Set Enrichment
Analysis [24] of the ranked clusters gave rise to gene sets down-
regulated in rings and trophozoites and up-regulated in schizonts in the
resistant parasites as shown ordered by the nominal p-value, false
discovery rate (FDR) q-value and Normalized Enrichment Score (NES).
Significant gene sets were based on cut-off p-value of 0.05 and FDR q-
value of 0.25.
Additional file 7: Functional pathways with significant differential
expression in rings, trophozoites and schizonts of artemisinin
resistant and sensitive parasites. Gene sets (functional groups) which
are denoted in the graphs are obtained from various data sets of
previous studies [63,66,70] and plotted are all pathways that are
significantly differentially expressed in artemisinin resistant parasites in at
least one IDC stage. For each pathway, each data point at ring (14 hpi),
trophozoite (26 hpi) and schizont (34 hpi) of the resistant (green triangle)
and sensitive (blue diamond) series was calculated from taking the
average of the expression log2 ratio of a gene across all isolates in that
phenotypic group (resistant or sensitive) and then averaged for all the
genes associated with that pathway. Best fit polynomial curves were
plotted (lines). Error bars indicate the standard deviation among the
isolates for that pathway. Included separately are the average expression
ratios of all genes belonging to that pathway for CP022 isolate (purple
circle) from Pailin, Cambodia and reference in vitro strain (red square).
Additional file 8: Relative expression of individual genes associated
with four functional pathways that have significant differential
expression in artemisinin resistant parasite. Top: Example of four
functional gene sets with significant differential expression between
resistant and sensitive parasites and the relative gene expression of all
members of the gene sets at the three stages. Each set of data points
are the average log2 expression ratios of the isolates in a group and
averaged for all the genes in that pathway at 14, 26 and 34 hpi. The
curves are the best fit polynomial curves to the data points. Bottom:
Each of the 3 graphs plotted depict the average log2 gene expression
ratios of the isolates in the resistant (green triangle) or sensitive (blue
diamond) group with the standard deviation represented by error bars in
each particular pathway at14, 26 or 34 hpi.
Additional file 9: Transcriptional profiles of the 3 genes in the
artemisinin resistant parasites compared with previous data
published [18]. The mean expression log2 ratio (data point) and SD
(error bars) among the resistant (green triangle) and sensitive (blue
diamond) isolates for each stage are plotted for the genes: PF10_0121 -
hypoxanthine phosphoribosyltransferase (rank 3207/4029; p-value = 0.1),
PF08_0054 - Heat Shock Protein 70 kDa (rank 14/4041; p-value = 0.0004)
and PFE1415w- cell cycle regulator (rank 3837/4041; p-value = 0.01). The
polynomial represents the best fit curve through the data points. The
arrow indicates the approximate stage in which significant increased or
lowered expression was observed in artesunate-tolerant parasites and the
fold change [18] (Witkowski et al., 2010).
Additional file 10: Functional analysis and clustering based on
general differences in gene expression among field isolates without
phenotypic classification. (a) Clusters are represented by the log2
expression ratios for all genes ordered according to the standard
deviation (SD) for each gene in a descending manner. GSEA [24]
performed on this pre-ranked list of genes identified these functional
gene sets as differentially expressed among field isolates without any
phenotypic classification for the 3 stages. (b) Hierarchically clustered
isolates for the genes showing greatest variation in expression ratios
(taking genes with SD value at the 95
th percentile cut off). Each color
denotes the location: Laos, Mae Sot or Pailin that the isolates originate
from. The raw data reported in this paper has been deposited in the
NCBI’s Gene Expression Omnibus database [71] and are accessible
through GEO Series accession number GSE25883. http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE25883
List of abbreviations used
IDC: Intra-erythrocytic developmental cycle; hpi: hours post invasion; PCT:
Parasite clearance time; SRCC: Spearman rank correlation coefficient; PCC:
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enrichment score; GSEA: Gene set enrichment analysis; KEGG: Kyoto
Encyclopedia of Genes and Genomes; MPM: Malaria metabolic pathway
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